Publicaciones en colaboración con investigadores/as de Universitat de València (8)

2024

  1. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

    Clinical and Translational Oncology

  2. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

2023

  1. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375

  2. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

    Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4166-4177

  3. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2647-2664

  4. Spatial predictors of immunotherapy response in triple-negative breast cancer

    Nature, Vol. 621, Núm. 7980, pp. 868-876

2012

  1. Pathological complete response rates following different neoadjuvant chemotherapy regimens for Operable Breast Cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

    Breast Cancer Research and Treatment, Vol. 132, Núm. 3, pp. 843-851

2002

  1. Pemetrexed in bladder, head and neck, and cervical cancers

    Seminars in Oncology, Vol. 29, Núm. 6 SUPPL. 18, pp. 69-75